Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives
- 1.3k Downloads
CD4+CD25+Foxp3+ Treg is a functionally distinct subset of mature T cells with broad suppressive activity and has been shown to play an important role in the establishment of immune tolerance after HSCT. Altered cytokine environment in post-HSCT lymphopenia with a relative functional deficiency of IL-2 could hamper the reconstitution of Treg, leading to refractory GVHD. Based on the theory of low-dose IL-2 in which Treg can be selectively stimulated through the high-affinity IL-2 receptor, clinical studies have been conducted and demonstrated that low-dose IL-2 administration can restore Treg homeostasis and promote the expansion of this subset on the polymorphic processes of Treg reconstitution after HSCT. The new therapeutic indication of IL-2 for immune tolerance has launched in the field of HSCT and is spreading to the other fields including the treatment for autoimmune diseases. To further extend the indication of low-dose IL-2 to more patients with various immunological problems, the optimization of the timing and dosing of IL-2 intervention and the concomitant immune suppressive therapy according to each patient-based assessment are to be desired in the near future. Further prospective studies may facilitate the development of novel therapeutic algorithms for the effective and safe induction of immune tolerance after HSCT.
KeywordsInterleukin-2 Graft-versus-host disease Regulatory T cell Immune tolerance
T-cell reconstitution after HSCT
T-cell reconstitution after HSCT is the polymorphic and long-term process. In general, the initial phase of T-cell reconstitution is primarily dependent on peripheral expansion of mature T cells that are present in the donor stem-cell graft [20, 21]. This is promoted by lymphopenia-related signals as well as stimulation by allo-antigens . Hematopoietic stem cells also migrate to the thymus and differentiated T cells are exported into periphery. However, thymus-dependent generation of donor T cells is generally delayed and incomplete in adult patients because of natural thymic involution and damage resulting from high-dose chemotherapy and irradiation administered as parts of the conditioning regimen . Once naïve T cells are exported into the periphery from thymus, these cells are subject to homeostatic signals that regulate the expansion and contraction of the T-cell population to maintain total numbers of T-cell subsets at appropriate levels in the circulation and peripheral lymphoid tissues. Although the transition of peripheral T-cell source from mature T cells in the stem-cell graft into thymic-generated naïve T cells is commonly observed in each T-cell lineage after HSCT, each T-cell subsets are subject to distinct homeostatic controls in the periphery . Particularly, Treg homeostasis appears to be distinct from conventional CD4 T cells (Tcon) and this may contribute to imbalance between Treg and Tcon [24, 25]. We previously studied the long-term Treg reconstitution after clinical HSCT and reported that thymic generation of Treg was markedly impaired but that this subset maintained a significantly higher level of proliferation compared to Tcon . Treg proliferation in vivo appeared to be driven primarily by CD4 lymphopenia. Importantly, high levels of Treg proliferation were counterbalanced by increased susceptibility to apoptosis in this subset. Our prospective monitoring study demonstrated the critical role of CD4 lymphopenia in the recovery of Treg and the selective peripheral depletion of Treg in response to this prolonged homeostatic pressure. The depletion of peripheral Treg was also associated with the development of chronic GVHD.
Basic framework of Treg reconstitution
Based on the findings, we here propose the basic framework of Treg reconstitution after HSCT, as shown in Fig. 2. It is constituted of four phases: Treg expansion, transition, repopulation, and maintenance. Though previous studies have suggested that host-type Treg showed a temporary expansion just after HSCT after nonmyeloablative conditioning, the kinetics of host-Treg after HSCT is left out from this schema to simply discuss the donor-Treg engrafting processes.
Phase 1: expansion of graft-derived Treg
In the first month post-HSCT, stem-cell graft-derived mature Tregs promptly expand in response to lymphopenia as well as allo-antigens. The expansion peaks around the first month after HSCT and appears to contract by activation-induced cell death (AICD). It still remains unclear whether some part of graft-derived Treg would survive or not as functionally-memory suppressor cells for a long time after HSCT .
Phase 2: transition of peripheral Treg source
The emergence of thymus-derived Treg is generally delayed because of thymic dysfunction after HSCT; therefore, the total Treg number in periphery once decreases after the contraction of graft-derived Tregs (transitional phase). The “dip” in Treg number in this phase may be associated with the onset of late-acute GVHD or overlap syndrome in the clinical situation.
Phase 3: repopulation and relocation of thymus-generated Treg
After a “dip” in Treg number in Phase 2, circulating Treg number increases and approaches to the normal range within a year. It is much faster than reconstitution of Tcon subsets those often reach a normal range over 2 years. Treg repopulation in this phase is mainly constituted by thymus-generated Treg cells. Though thymic Treg generation is markedly impaired after HSCT, newly-generated Tregs keep the increased levels of proliferation over the phase. The proliferation is relatively aggressive as compared to other conventional T cells, resulting in the high levels of Treg/Tcon ratio and Treg/CD8T ratio in the phase  .
Phase 4: maintenance of thymus-generated Treg
Because only naïve Tregs are capable of aggressive proliferation, the stable emergence of naïve Treg from thymus can be thought to be critical for the maintenance of Treg homeostasis. Treg can repopulate by compensatory homeostatic proliferation in Phase 3 even in patients with severe thymic damage; however, high levels of Treg proliferation in the prolonged lymphopenia become to be counterbalanced by increased susceptibility to apoptosis 6–9 months after HSCT. Importantly, the peripheral depletion based on the abnormal homeostasis is observed just in Treg cells, not in other conventional T cells, resulting in the unbalance of lymphocyte subsets which provide a fundamental basis of the development of chronic GVHD [8, 27, 28].
Intervention in Treg homeostasis by low-dose IL-2
As mentioned, Treg homeostasis in the post-HSCT environment tends to be unstable. Recent clinical studies suggested that the use of several immune-modulating agents in the peri-transplant period, including sirolimus, thymoglobulin, azacitidine, ruxolitinib, and post-transplant cyclophosphamide (PT-Cy), might be associated with the relative increase of Treg subset in the early phase after HSCT. While these agents might increase Treg in an indirect fashion, exogenous low-dose IL-2 directly acts on Treg homeostasis in a Stat5-dependent manner and can increase the subset. Murine studies demonstrated that exogenous administration of low-dose IL-2 increased Treg and resulted in the improvement of autoimmune symptoms and GVHD [15, 29]. Analyses of the clinical samples from patients who received low-dose IL-2 to enhance GVL effect after post-transplant relapse elucidated that low-dose IL-2 increase NK cells as well as Treg cells [14, 30]. Based on these findings, immune tolerance-oriented indication of IL-2 in the clinical setting has launched.
Previous trials can be divided into two groups by timing and purpose of IL-2 intervention. One is for the purpose of treatment for developed GVHD symptoms in Phase 4, and the other is for the purpose of prophylaxis of GVHD during Phases 1–3.
Therapeutic intervention in Treg homeostasis by low-dose IL-2
In Japan, we got back to a preclinical study with murine model of IL-2 therapy to reconsider the optimum algorism of IL-2 intervention for safe and efficient Treg expansion and found that the daily administration might not be required and the intermittent administration within threshold could be sufficient for the maintenance of expanded Treg after the initial intensive IL-2 intervention. Based on the idea, we have designed and started a multicenter phase I/IIa clinical trial of low-dose IL-2 for patients with steroid-refractory cGVHD . In our protocol, treatment is composed of two sequential phases: the induction phase and the maintenance phase. In the induction phase, IL-2 is subcutaneously administrated once per day for 4 weeks. In the subsequent maintenance phase, IL-2 is subcutaneously administrated three times per week for following 8 weeks. The study was just completed and data are being analyzed for publication and next pivotal phase of clinical trial.
Prophylactic intervention in Treg homeostasis by low-dose IL-2
The results from the Phase 2 study at Dana–Farber Cancer Institute suggest that low-dose IL-2 should start at the earlier timepoint when the rebuilding immunity still retains plasticity and the tissue damage remains mild. This may be related to the idea of the prophylactic use of low-dose IL-2. Several clinical trials of low-dose IL-2 for patients before developing GVHD have already conducted for the purpose of promoting the early Treg recovery and actively inducing tolerance (Fig. 3).
Huston group first tested the effect of prophylactic IL-2 for pediatric patients after HSCT . IL-2 (1–2 × 105 IU/m2/day) was daily administrated from days 30 to 120, which resulted in Treg increase in the first month after the initiation of IL-2. Remarkably, no patients developed acute GVHD grades 2–4 and the incidence of virus infection was significantly decreased than the historical control. A group from China conducted a larger scale randomized trial, where patients in the IL-2 arm were compared with patients without IL-2 . Patients in the IL-2 arm received subcutaneous injection of IL-2 (1 × 106 IU/m2/day) from day 60. IL-2 was administered daily for 14 days followed by a 14-day hiatus. Circulating Treg levels were elevated during the treatment periods. Incidence of chronic GVHD was significantly lower than control, while the cumulative incidence with the positive minimum residual disease (MRD) test was significantly higher in IL-2 cohort compared with the control cohort. Betts et al. conducted the very early IL-2 administration trial . 20 patients received IL-2 (2 × 105 IU/m2/day), thrice weekly, from days 0 to + 90. IL-2 administration resulted in the increase of Treg in the first month; however, it led to a fall in Tregs by day 90 and did not reduce acute or chronic GVHD. Interestingly, patients who discontinued IL-2 before day 100 showed a trend toward less acute GVHD grades 2–4.
These findings from the completed studies suggest that the prophylactic administration of low-dose IL-2 can successfully promote the early Treg expansion and it appears to contribute the suppression of acute and chronic GVHD. Since allo-stimulation is still aggressive and also the absolute number of Treg is much fewer in this prophylactic phase (Phases 1–3 in Fig. 2) as compared with the chronic phase (Phase 4 in Fig. 2), the delicate optimizing of IL-2 dosing is thought to be the key to sustain lasting Treg levels and induce tolerance [37, 38]. On the other hand, one study reported the significant increase of positive MRD test in patients received IL-2 prophylactically, suggesting that IL-2 might affect GVL effect at least partially. For this reason, it might be better to carefully follow the long-term influence of the early Treg modification by low-dose IL-2.
In the completed three trials introduced above, the enrolled patients were basically recipients of transplantation from HLA-matched donors. NIH group is conducting a clinical trial to extend the indication of prophylactic low-dose IL-2 toward haplo-identical transplantation. Patients receive haplo-identical donor grafts with posttransplant cyclophosphamide followed by daily administration of low-dose IL-2 (1 × 105 IU/m2) for 12 weeks starting day 1 (ClinicalTrials.gov Identifier: NCT02226861). In this setting, it would be theoretically expected that NK cell-based anti-tumor immunity could be enhanced with exogenous IL-2, leading to a possibility of clearly separating GVL from GVHD .
Clinical studies of low-dose IL-2 in the past decade have shown the feasibility and the efficacy of this treatment. To extend the indication of low-dose IL-2 to more patients with various immunological problems such as severe thymic involution, malignant cancer, and refractory autoimmune diseases, several combination therapies with IL-2 were worthy to be taken into consideration.
Low-dose IL-2 combined with donor-Treg infusion
Low-dose IL-2 combined with checkpoint blockade
We recently demonstrated that PD-1 is a critical homeostatic regulator for Treg by modulating proliferation and apoptosis during IL-2 therapy . This study showed that exogenous IL-2 promptly induces the expression of PD-1 particularly on central-memory Tregs and increased PD-1 expression was maintained during IL-2 therapy. Of note, PD-1 blockade negated the effects of IL-2, promoted Treg apoptosis, and reduced Treg numbers in vivo. In HSCT patients after receiving PD-1 blockade, it might be needed to consider the indication of low-dose IL-2 with caution. However, if viewed from the opposite side, it may means that PD-1 inhibition of Tregs may provide an additional mechanism, whereby PD-1 blockade promotes effective tumor immunity in patients with cancer.
Application for autoimmune diseases
Completed clinical trials of low-dose IL-2 for GVHD and other autoimmune diseases
Schedule of IL-2 administration
Steroid-refractory chronic GVHD
1 × 106 IU/m2/day, daily administration for 8–12 weeks
52–61% clinical response
1–2 × 105 IU/m2/day, daily administration from day 30 to day 120
No grade II–IV aGVHD
1 × 106 IU/m2/day, daily administration for 14 days followed by a 14-day hiatus, from day 60
Less moderate-to-severe chronic GVHD
2 × 105 IU/m2/day, administration thrice weekly, from days 0 to 90
Less grade II–IV aGVHD (if IL-2 discontinued early)
1–3 × 106 IU/m2/day from days 1 to 5 every 21 days, 4 courses
90% Clinical response
Systemic lupus erythematosus
1 × 106 IU/m2/day every other day for 14 days, 3–6 courses
95% Clinical response
1–3 × 106 IU/m2/day from days 1 to 5 every 21 days, 4 courses
80% Clinical response
0.3–3 × 106 IU/m2/day, daily administration for 5 days
Selective Treg increase
The present review provides a summary of the previous studies of low-dose IL-2 therapy for patient after allogeneic HSCT. New indication of IL-2 for immune tolerance was proposed from the field of HSCT and thereafter extending to the field of autoimmunity within just a few years, suggesting the study of clinical GVHD could be an important platform to develop new cellular therapy for various autoimmune diseases widely. Treg reconstitution after HSCT is basically polymorphic and varies in each patient; therefore, the appropriate timing and dosing of IL-2 intervention should be considered according to each patient-based immune monitoring in the near future. Further prospective studies may facilitate the development of novel therapeutic algorithms for the effective and safe induction of immune tolerance after HSCT.
- 30.Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R, et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(3):382–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014;20(8):2215–25.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Satake A, Schmidt AM, Nomura S, Kambayashi T. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation. PLoS One. 2014;9(3):e92888.CrossRefPubMedPubMedCentralGoogle Scholar